share_log

JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target

JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target

JMP證券重申CRISPR Therapeutics的市場表現跑贏大盤,維持86美元的目標股價
Benzinga ·  05/09 14:24

JMP Securities analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $86 price target.

JMP Securities分析師西爾文·圖爾克坎重申CRISPR Therapeutics(納斯達克股票代碼:CRSP)的市場跑贏大盤,並維持86美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論